- Home
- NRXS vs MIRA Comparison
NRXS vs MIRA Comparison
Compare NRXS & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXS
- MIRA
- Stock Information
- Founded
- NRXS 2011
- MIRA 2020
- Country
- NRXS United States
- MIRA United States
- Employees
- NRXS N/A
- MIRA N/A
- Industry
- NRXS
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- NRXS
- MIRA Health Care
- Exchange
- NRXS Nasdaq
- MIRA Nasdaq
- Market Cap
- NRXS 25.8M
- MIRA 25.2M
- IPO Year
- NRXS 2023
- MIRA 2023
- Fundamental
- Price
- NRXS N/A
- MIRA $1.33
- Analyst Decision
- NRXS Strong Buy
- MIRA
- Analyst Count
- NRXS 1
- MIRA 0
- Target Price
- NRXS $7.00
- MIRA N/A
- AVG Volume (30 Days)
- NRXS 54.3K
- MIRA 886.3K
- Earning Date
- NRXS 11-11-2025
- MIRA 11-11-2025
- Dividend Yield
- NRXS N/A
- MIRA N/A
- EPS Growth
- NRXS N/A
- MIRA N/A
- EPS
- NRXS N/A
- MIRA N/A
- Revenue
- NRXS $3,217,531.00
- MIRA N/A
- Revenue This Year
- NRXS $62.14
- MIRA N/A
- Revenue Next Year
- NRXS $131.87
- MIRA N/A
- P/E Ratio
- NRXS N/A
- MIRA N/A
- Revenue Growth
- NRXS 41.93
- MIRA N/A
- 52 Week Low
- NRXS $1.33
- MIRA $0.73
- 52 Week High
- NRXS $6.20
- MIRA $2.56
- Technical
- Relative Strength Index (RSI)
- NRXS N/A
- MIRA 46.68
- Support Level
- NRXS N/A
- MIRA $1.28
- Resistance Level
- NRXS N/A
- MIRA $1.36
- Average True Range (ATR)
- NRXS 0.00
- MIRA 0.06
- MACD
- NRXS 0.00
- MIRA 0.00
- Stochastic Oscillator
- NRXS 0.00
- MIRA 60.00
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.